Board approved acquisition of 100% equity capital of iSERA Biological Limited via share swap for ₹78.01 crore consideration.
Authorized share capital increased from ₹11 crore to ₹25 crore to facilitate the preferential issue of 1.62 crore shares.
Valuation reports fixed fair value at ₹48.20 per share for both companies, resulting in a 1:1 swap ratio.
Approved adoption of new Memorandum and Articles of Association to align with Companies Act 2013 provisions.